| Identification | Back Directory | [Name]
Ianalumab | [CAS]
1929549-92-7 | [Synonyms]
Ianalumab
Ianalumab (anti-TNFRSF13C)
Research Grade Ianalumab (DHJ42201) |
| Hazard Information | Back Directory | [Uses]
Ianalumab (VAY-736) is a human, decarboxylated antibody against BAFF-R. Ianalumab can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF. Ianalumab exerts antibody-dependent cytotoxic (ADCC), depending on effector cell activation mediated by immune receptor tyrosine activation motif (ITAM)[1]. | [in vivo]
Ianalumab (Total: 100 mg/kg; once weekly for 2 weeks) increases in vivo survival in CLL mouse models[1].
Ianalumab (10 mg/kg; once weekly for 6 weeks) is enhanced by Ibrutinib (HY-10997) through an ITAM function on NK cells[1]. | Animal Model: | Em-TCL1 adoptive transplant model of murine CLL[1] | | Dosage: |
10 mg/kg | | Administration: |
Injection; once weekly for 6 weeks | | Result: | Ibrutinib enhanced VAY-736 activity through an ITAM function on NK cells.
|
| [References]
[1] McWilliams EM, et al. Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib. Blood Adv. 2019 Feb 12;3(3):447-460. DOI:10.1182/bloodadvances.2018025684 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
|